SELLAS Life Sciences Group, Inc.
(NASDAQ : SLS)

( )
SLS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.37%86.271.3%$1274.24m
AMGNAmgen Inc.
0.97%203.881.2%$676.03m
GILDGilead Sciences, Inc.
0.77%69.180.9%$577.80m
LOXOLoxo Oncology Inc
0.11%233.5012.7%$474.39m
BIIBBiogen Inc.
-0.27%337.421.3%$459.87m
ILMNIllumina, Inc.
0.87%312.753.5%$351.51m
VRTXVertex Pharmaceuticals Incorporated
2.19%194.701.9%$332.94m
REGNRegeneron Pharmaceuticals, Inc.
0.35%418.842.6%$322.26m
ALXNAlexion Pharmaceuticals, Inc.
2.12%117.052.0%$239.80m
TSROTESARO, Inc.
0.03%74.9614.4%$196.22m
AAgilent Technologies, Inc.
2.10%72.311.5%$166.45m
EXASExact Sciences Corporation
4.19%78.8025.3%$156.07m
INCYIncyte Corporation
-0.32%78.422.5%$153.20m
SRPTSarepta Therapeutics, Inc.
1.22%122.8015.4%$142.40m
LGNDLigand Pharmaceuticals Incorporated
6.49%117.9023.1%$123.00m

Company Profile

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. The company was founded on April 3, 2006 and is headquartered in New York, NY.